Sensei Biotherapeutics (NASDAQ:FTH) Upgraded to Sell at Wall Street Zen

Posted by Geri Gentry on Aug 9th, 2026

Wall Street Zen upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday morning.

FTH has been the topic of a number of other reports. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, May 28th. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price objective on the stock. Oppenheimer started coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Finally, Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.90.

Read Our Latest Report on Sensei Biotherapeutics

Sensei Biotherapeutics Stock Performance

NASDAQ FTH opened at $24.39 on Friday. The company has a market cap of $32.68 million, a P/E ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics has a twelve month low of $7.20 and a twelve month high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. Research analysts predict that Sensei Biotherapeutics will post -13.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson bought 9,391 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the purchase, the chief financial officer owned 26,804 shares in the company, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder James Peyer sold 25,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders bought 49,494 shares of company stock valued at $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the first quarter valued at $4,188,000. Finally, Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the 1st quarter worth about $22,758,000. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

Positive Sentiment: HC Wainwright significantly improved its long-term outlook. The analyst raised projected EPS for fiscal 2026 to a loss of $13.54 from $16.61, fiscal 2027 to a loss of $2.68 from $3.72, fiscal 2028 to a loss of $2.37 from $3.19, fiscal 2029 to a loss of $2.25 from $3.16, and fiscal 2030 to a loss of $2.54 from $3.07. Quarterly loss estimates for late 2026 and 2027 were also reduced. The firm maintained a Buy rating and a $60 price target, implying substantial upside from recent trading levels. HC Wainwright estimate revisions
Positive Sentiment: JonesTrading initiated coverage of Sensei Biotherapeutics. New analyst coverage can increase investor attention and potentially improve liquidity, although the report’s rating and price target were not provided. JonesTrading Begins Coverage on Sensei Biotherapeutics
Neutral Sentiment: Faeth announced inducement grants to two new employees. The awards cover options to purchase 11,000 shares under the company’s 2026 Inducement Plan. Hiring may support corporate development, but the grants could modestly dilute existing shareholders and are unlikely to materially affect the stock by themselves. Faeth Therapeutics Announces Inducement Grants

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.